Navigation Links
NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting
Date:10/13/2008

hich have previously been presented from this trial. This hypothesis will be tested in the ongoing multicenter Phase III registration trial."

Dr. Brown's analysis examined over 1400 images from patients enrolled in the company's ongoing Phase II pilot study, which includes 34 trial participants (with a mean age of 72 years) treated from June 2006 to April 2007 at two centers in Brazil and one in Mexico. These patients, with predominantly classic, minimally classic, or occult (with no classic) choroidal neovascularization (CNV), received a single 24 Gy treatment of NeoVista's epiretinal brachytherapy in combination with two intravitreal injections of an anti-VEGF agent (bevacizumab), which are delivered to maximize the acute therapeutic response. Preliminary data show that NeoVista's targeted radiation therapy is well tolerated and may provide a new approach to restore the patient's vision and improve their quality of life.

"Dr. Brown's analysis is providing valuable information on our novel technology," said John N. Hendrick, President and CEO of NeoVista. "For someone with his credibility and expertise in the field of retinal medicine to independently analyze and present this data is quite encouraging and provides further proof of concept of our technique. We know that the mechanism of action of radiation is different from any therapy currently available for wet AMD and we look forward to the potential promise of significantly decreasing the burden of wet AMD therapy."

The observational analysis was presented at ASRS while NeoVista continues to enroll patients in the company's pivotal Phase III trial, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy). CABERNET is a multicenter, randomized, controlled study that will enroll 450 subjects at 45 sites worldwide, evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis(R) (ranibizum
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer
2. The Lewin Group Presents McCain and Obama Health Policies: Cost and Coverage Compared Analysis
3. Stater Bros. Markets Presents $1,143,000 Check to Muscular Dystrophy Association
4. Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford
5. AMA Foundation Presents the Arthur N. Wilson, MD Scholarship to Promising Medical Student From Southeast Alaska
6. USA-ONE Interactive Presents a Free Webinar Series Introducing Docuvation – An Online Document Management Solution
7. AMA Foundation Presents $10,000 Scholarships to Promising Medical Students
8. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
9. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
10. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
11. ExonHit Presents Therapeutic and Diagnostic Programs for Alzheimers at ICAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
...ions, a leading provider of nationwide nursing and...h approach to its Referral Rewards Program, which ... new laptop computer. , O...h approach to its Referral Rewards Program, which ...
..., ST. LOUIS, Oct. 20 KV Pharmaceutical Company,(... by Hologic, Inc., the,holder of the New Drug Appl...and Drug Administration (FDA) has extended the PDU...g procedure,when it receives updated data from the...
...sted collagen, study says , , MONDAY, Oct....rs to cause molecular-level changes in aging skin ... appearance, a U.S. study finds. , In photodynamic... topical medication, such as 5-aminolevulinic acid...
...es risk of chronic diseases and,can help reduce he... CHICAGO, Oct. 20 Small steps can lead to big,he...Life Steps campaign,launched today. As families st...festyle at little or no cost. New,resources and to...
... will be critical when determining, the impact of ...nd on the availability of, and accessibility...0 Stuart Chesky, DO, JD, Medical,Director of Ohio...es in Health Care Contracts. The Commission was,es...
...e, study suggests , , MONDAY, Oct. 20 (Hea...ly to die in U.S. emergency rooms after a trauma t...over, uninsured ER patients are more likely to die...ntly influences survival after trauma," said lead ...
Other Medicine News:Health News:Healthcare Staffing Company, Medical Solutions Now Offers More Than Just Cash as Part of its Referral Rewards Program 2Health News:KV Provides Update on Gestiva(TM) PDUFA Date 2Health News:KV Provides Update on Gestiva(TM) PDUFA Date 3Health News:KV Provides Update on Gestiva(TM) PDUFA Date 4Health News:Light-Activated Therapy Seems to Rejuvenate Aging Skin 2Health News:AMA Aims to Help Americans Get Healthier One Step at a Time 2Health News:Stuart Chesky, DO, JD, Ohio KePRO Medical Director, Appointed to Ohio Joint Legislative Study Commission on Most Favored Nation Clauses in Health Care Contracts 2Health News:Stuart Chesky, DO, JD, Ohio KePRO Medical Director, Appointed to Ohio Joint Legislative Study Commission on Most Favored Nation Clauses in Health Care Contracts 3Health News:Minorities More Likely to Die in ER 2Health News:Minorities More Likely to Die in ER 3
(Date:12/4/2009)Opposes use of imported drugs often stored in tin cans and car trunks ,, WASHINGTON, Dec. 4 Today, the senior advocacy group RetireSafe urged the Senate to defeat the Dorgan Importation plan encomp
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
Breaking Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Stillbirth Not an Issue for Next Born 51358 1Stillbirth Not an Issue for Next Born 51358 2Researchers consider herd movements to help eradicate bovine TB 51355 1Researchers consider herd movements to help eradicate bovine TB 51355 2Texas Humane Legislation Network Calls for Puppy Mill Crackdown 51352 1Texas Humane Legislation Network Calls for Puppy Mill Crackdown 51352 2
...akland), Sponsored by AIDS Healthcare Foundation,(...thern California,HIV/AIDS Coalition (SCHAC) Could ...ong California Inmates, Governor Instructs Depart...ribution Program in California; AHF Notes Successf..., New York, Philadelphia and Washington,Already Sh...
...t Millions Who Suffer From Condition, NEW YORK, O... drug-eluting (dispensing), stents can benefit pat...(PAD) is taking place at,Montefiore Medical Center...,the study. Medicated, drug-coated stents have be...ars in treating coronary artery disease. PAD affe...
Other Medicine Technology:Veto of California's Condoms in Prisons Bill: "Politics Over Public Health," Says AHF 2Veto of California's Condoms in Prisons Bill: "Politics Over Public Health," Says AHF 3Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore 2
Blunt electrode
J-Hook Electrode
... The 5mm AEM Laparoscopic Instruments incorporate ...uments are shielded and monitored to prevent stray...rument caused by insulation failure or capacitive ...he protective shield built into all AEM Instrument...
... The 5mm AEM Laparoscopic Instruments incorporate ...uments are shielded and monitored to prevent stray...rument caused by insulation failure or capacitive ...he protective shield built into all AEM Instrument...
Medicine Products: